Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience

BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...

Full description

Saved in:
Bibliographic Details
Published in:Case Rep Oncol Med
Main Authors: Karivedu, Vidhya, Eldessouki, Ihab, Taftaf, Ahmad, Zhu, Zheng, Makramalla, Abouelmagd, Karim, Nagla Abdel
Format: Artigo
Language:Inglês
Published: Hindawi 2019
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501230/
https://ncbi.nlm.nih.gov/pubmed/31179139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3560640
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items